• Title/Summary/Keyword: botulinum toxin

Search Result 217, Processing Time 0.029 seconds

A Case of Paradoxical Vocal Fold Movement with Severe Respiratory Distress (심한 호흡곤란을 동반한 역설성성대운동 1예)

  • Park, Jun Woo;Kim, Ji Won;Lim, Chae-Man;Choi, Seung-Ho
    • Journal of the Korean Society of Laryngology, Phoniatrics and Logopedics
    • /
    • v.26 no.1
    • /
    • pp.51-53
    • /
    • 2015
  • Paradoxical vocal fold movement (PVFM) is characterized by aberrant vocal fold adduction. Although the exact pathogenesis is unknown, botulinum toxin injection, behavioral techniques, including speech therapy, bio-feedback, and cognitive-behavioral psychotherapy are considered for treatment of PVFM. The effectiveness of these treatments is not fully evaluated because of the rarity of disease. We present a case of 16-year-old female with sudden onset of respiratory distress associated with PVFM refractory to several treatments and spontaneously resolved later.

  • PDF

A Treatment Experience of Focal Hyperhidrosis in Sacrococcygeal Region -A report of two cases- (천미골 국소 다한증 환자의 치료 경험 -증례 보고-)

  • Yoon, Kyung Bong;Kim, Won Oak;Yoon, Duck Mi;Lee, Yoon Chang;Park, Joon Hee;Hong, Nam Geun
    • The Korean Journal of Pain
    • /
    • v.18 no.1
    • /
    • pp.89-91
    • /
    • 2005
  • Essential hyperhidrosis is a socially disabling and emotionally embarrassing condition. Localized excessive sweating in the sacrococcygeal region is a rare form of focal hyperhidrosis. Although numerous treatment options exist, including botulinum toxin and sympathetic neurolysis, there has been no generally accepted form of treatment. The following cases describe the successful reduction of excessive sweating in the sacrococcygeal region, without side effects, after local applications of topical glycopyrrolate and the use of fast drying clothes.

Lesch-Nyhan syndrome: a case report

  • Han Ick Park;Gu-Hwan Kim;Kang-Min Ahn
    • Journal of the Korean Association of Oral and Maxillofacial Surgeons
    • /
    • v.49 no.4
    • /
    • pp.228-232
    • /
    • 2023
  • Lesch-Nyhan syndrome (LNS) is a rare X-linked recessive disorder caused by a mutation in the hypoxanthine phosphoribosyltransferase 1 (HPRT1) gene. This syndrome is characterized by excessive production of uric acid, mental retardation, self-mutilation, choreoathetosis, and spasticity. The most distinctive symptom is compulsive self-mutilation. For patients with LNS, different methods have been tried to reduce self-biting behaviors including restraints, behavioral treatment, medications, deep brain stimulation, tooth extraction and botulinum toxin A injection. In this report, we present a case of LNS undergoing cheiloplasty due to self-mutilation and tooth extraction of the left deciduous maxillary canine.

Fine-Tuned ProtBERT for Toxic Protein Classification (ProtBERT를 활용한 독성 단백질 분류)

  • Ahn, Sung-Yoon;Lee, Sang-Woong
    • Proceedings of the Korean Society of Computer Information Conference
    • /
    • 2022.07a
    • /
    • pp.673-674
    • /
    • 2022
  • 살아있는 유기체에 의해 분비되는 독소는 대부분의 경우 인간에게 유해하다. 가령 여름철 날것이나 오래된 음식에서 쉽게 식중독에 걸릴 수 있는데, 이는 주로 Clorustidium Botulinum이 만들어낸 보툴리눔 독소가 원인이다. 유기체에 의해 생성된 모든 독소는 단백질이며 이는 아미노산 서열로 나타낼 수 있다. 이를 통해 생물정보학 분야의 많은 연구자들이 많은 머신러닝 기술을 통해 단백질의 독성을 예측할 수 있었다. 최근 몇 년 동안 SVM를 사용하는 BTXpred와 CNN을 사용하는 ToxDL과 같은 모델이 각각 박테리아와 동물 독소의 독성을 예측하기 위해 제안되었다. 시대가 변함에 따라 BERT와 같은 성능이 더욱 뛰어난 모델이 시퀀스 분류를 위해 도입되었다. 본 논문은 독성 단백질을 분류를 위해 ProtBERT를 사용할 경우 이의 성능을 보여주고자 한다.

  • PDF

Neuromodulation for Atrial Fibrillation Control

  • Seil Oh
    • Korean Circulation Journal
    • /
    • v.54 no.5
    • /
    • pp.223-232
    • /
    • 2024
  • Trigger and functional substrate are related to the tone of autonomic nervous system, and the role of the autonomic nerve is more significant in paroxysmal atrial fibrillation (AF) compared to non-paroxysmal AF. We have several options for neuromodulation to help to manage patients with AF. Neuromodulation targets can be divided into efferent and afferent pathways. On the efferent side, block would be an intuitive approach. However, permanent block is hard to achieve due to completeness of the procedure and reinnervation issues. Temporary block such as botulinum toxin injection into ganglionated plexi would be a possible option for post-cardiac surgery AF. Low-level subthreshold stimulation could also prevent AF, but the invasiveness of the procedure is the barrier for the general use. On the afferent side, block is also an option. Various renal denervation approaches are currently under investigation. Auditory vagus nerve stimulation is one of the representative low-level afferent stimulation methods. This technique is noninvasive and easy to apply, so it has the potential to be widely utilized if its efficacy is confirmed.

Nocturnal Bruxism and Botulinum Toxin Effect on the Subjects with Masseteric Hypertrophy (야간 이갈이와 교근비대 환자의 보툴리눔 독소 주사 효과)

  • Sohn, Seung-Mahn;Chung, Gi-Chung;Kim, Mee-Eun;Kim, Ki-Suk
    • Journal of Oral Medicine and Pain
    • /
    • v.32 no.3
    • /
    • pp.337-346
    • /
    • 2007
  • This study aimed to evaluate a relation of bruxism with clinical effects of botulinum toxin type A(BTX-A) injection. 5 bruxers and 5 nonbruxers with bilateral masseter hypertrophy were participated in this study. After injecting 25 unit of BTX-A(Allergen Inc, $Botox^{(R)}$) into each masseter muscle, the thickness of masseter(Mm) and anterior temporalis(Ta) muscles was measured by ultrasonography and the maximum bite force was evaluated during a 9-month period. Self-estimation on the recovery of occlusal force during mastication was done as well. Regardless of presence of bruxsim, all subjects showed significantly reduced Ms thickness(p<0.001) and maximum bite force at $1^{st}$ molars(p=0.027) with their peak at 3 months after injection, which then started to return. No significant difference was observed in Ta thickness and the bite force at the central incisors. While self-estimated occlusal force was the least at 2 weeks after injection and then rapidly returned to the baseline level with full recovery at the time of 6 to 9 months after injection, the maximum bite force measured by bite force recorder did not recover the original value, particularly in the nonbruxer group. It is assumed that nocturnal bruxism can influence recovery of atrophic masseter and decreased occlusal force due to BTX-A injection. These findings suggest a need of occlusal appliance to control bruxism or clenching habit for longer clinical effect of BTX-A injection.

Analysis of treatment patterns of temporomandibular disorders (측두하악장애 치료유형 분석)

  • Cha, Yong-Hoon;Kim, Bum-Joon;Lim, Jae-Hyung;Park, Kwang-Ho;Kim, Hyung-Gon;Huh, Jong-Ki
    • Journal of the Korean Association of Oral and Maxillofacial Surgeons
    • /
    • v.36 no.6
    • /
    • pp.520-527
    • /
    • 2010
  • Introduction: This study examined the treatment patterns of temporomandibular disorders (TMD) including conservative and surgical procedures. Materials and Methods: Patients with TMD who visited Gangnam Severance Hospital from June 2007 to May 2008 were enrolled in this study. All patients were examined from the orthopantomogram, temporomandibular joint (TMJ) tomography, and a clinical examination. The patients who required a further evaluation were examined by magnetic resonance imaging and/or computed tomography. The treatment patterns were divided into counseling, medication, splint therapy, botulinum toxin injection (BTI) and surgical treatment. Results: Among the 2,464 patients, the average age was 31.8 years (ranging from 6 to 93); 764 (31.0%) were male and 1,700 (69.0%) were female. 2,355 (95.6%) patients were treated with conservative therapy; 1,460 (62.0%) patients were treated with medication, 931 (39.5%) patients were treated with splint, and 46 (2.0%) were treated with BTI. There were 109 (4.4%) patients treated surgically. Eight (0.3%) patients were treated with total temporomandibular joint replacement surgery. Conclusion: Almost all patients with TMD were treated using conservative methods. Those patients who received surgical treatment because of an ineffective response to conservative treatment had definite problems with the internal derangement and/or osteoarthritis or had severe clinical symptoms.

Comparative Study of Multimodal Therapy in Facial Palsy Patients

  • Neville, Catriona;Gwynn, Tamsin;Young, Karen;Jordan, Elizabeth;Malhotra, Raman;Nduka, Charles;Kannan, Ruben Yap
    • Archives of Plastic Surgery
    • /
    • v.49 no.5
    • /
    • pp.633-641
    • /
    • 2022
  • Introduction In chronic facial palsy, synkinetic muscle overactivity and shortening causes muscle stiffness resulting in reduced movement and functional activity. This article studies the role of multimodal therapy in improving outcomes. Methods Seventy-five facial palsy patients completed facial rehabilitation before being successfully discharged by the facial therapy team. The cohort was divided into four subgroups depending on the time of initial attendance post-onset. The requirement for facial therapy, chemodenervation, or surgery was assessed with East Grinstead Grade of Stiffness (EGGS). Outcomes were measured using the Facial Grading Scale (FGS), Facial Disability Index, House-Brackmann scores, and the Facial Clinimetric Evaluation scale. Results FGS composite scores significantly improved posttherapy (mean-standard deviation, 60.13 ± 23.24 vs. 79.9 ± 13.01; confidence interval, -24.51 to -14.66, p < 0.0001). Analysis of FGS subsets showed that synkinesis also reduced significantly (p < 0.0001). Increasingly, late clinical presentations were associated with patients requiring longer durations of chemodenervation treatment (p < 0.01), more chemodenervation episodes (p < 0.01), increased doses of botulinum toxin (p < 0.001), and having higher EGGS score (p < 0.001). Conclusions This study shows that multimodal facial rehabilitation in the management of facial palsy is effective, even in patients with chronically neglected synkinesis. In terms of the latency periods between facial palsy onset and treatment initiation, patients presenting later than 2 years were still responsive to multimodal treatment albeit to a lesser extent, which we postulate is due to increasing muscle contracture within their facial muscles.

Rapid, Simultaneous Detection of Various Biological Toxin Genes Using Multiplex Reverse Transcription Loop-Mediated Isothermal Amplification(RT-LAMP) (다중 역전사-루프매개등온증폭법(RT-LAMP)를 이용한 생물 독소 유전자 신속 진단법)

  • Seungho Lee;Chanho Chung;Sehun Gu;Jungeun Kim;Hyeongseok Yun;Daesang Lee;Gyeunghaeng Hur;Donghyun Song
    • Journal of the Korea Institute of Military Science and Technology
    • /
    • v.27 no.4
    • /
    • pp.516-527
    • /
    • 2024
  • Rapid, early, accurate detection and identification of the various pathogenic agents associated with the development of biological weapons is critical in preventing loss of life and limiting the impact of these organisms when used against civilian or military targets. The aim of this study was to produce a system for the simple, rapid, accurate and simultaneous detection and identification of Ricin, Botulinum toxin B and Staphylococcal enterotoxin B as a proof of principle for developing field appropriate reverse transcription loop-mediated isothermal amplification systems for the accurate identification of potential biological threats. These systems were designed to facilitate the identification of potential threats even in remote or resource-limited locations.

Expression, Purification and Transduction of PEP-1-Botulinum Neurotoxin Type A (PEP-1-BoNT/A) into Skin

  • Kim, Dae-Won;Kim, So-Young;An, Jae-Jin;Lee, Sun-Hwa;Jang, Sang-Ho;Won, Moo-Ho;Kang, Tae-Cheon;Chung, Kwang-Hoe;Jung, Hyun-Ho;Cho, Sung-Woo;Choi, Jin-Hi;Park, Jin-Seu;Eum, Won-Sik;Choi, Soo-Young
    • BMB Reports
    • /
    • v.39 no.5
    • /
    • pp.642-647
    • /
    • 2006
  • Botulinum neurotoxin A (BoNT/A) has been used therapeutically to treat muscular hypercontractions and sudomotor hyperactivity and it has been reported that BoNT/A might have analgesic properties in headache. PEP-1 peptide is a known carrier peptide that delivers fulll-ength native proteins in vitro and in vivo. In this study, a BoNT/A gene were fused with PEP-1 peptide in a bacterial expression vector to produce a genetic in-frame PEP-1-BoNT/A fusion protein. The expressed and purified PEP-1-BoNT/A fusion proteins were efficiently transduced into cells in a time- and dose-dependent manner when added exogenously in a culture medium. In addition, immuno-histochemical analysis revealed that PEP-1-BoNT/A fusion protein efficiently penetrated into the epidermis as well as the dermis of the subcutaneous layer, when sprayed on mice skin. These results suggest that PEP-1-BoNT/A fusion protein provide an efficient strategy for therapeutic delivery in various human diseases related to this protein.